Literature DB >> 14680442

Review of cetirizine hydrochloride for the treatment of allergic disorders.

Jay M Portnoy1, Chitra Dinakar.   

Abstract

Cetirizine hydrochloride is an orally-active and selective histamine (H(1))-receptor antagonist. It is a second-generation antihistamine and a human metabolite of hydroxyzine. Therefore, its principal effects are mediated via selective inhibition of peripheral H(1) receptors. The antihistaminic activity of cetirizine has been documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In clinical studies, however, dry mouth has been seen more commonly with cetirizine than with placebo. In vitro receptor binding studies have shown no measurable affinity for receptors other than H(1) receptors. Auto-radiographical studies with radiolabelled cetirizine in the rat have shown negligible penetration into the brain. Ex vivo experiments in the mouse have shown that systemically administered cetirizine does not significantly occupy cerebral H(1) receptors. Impairment of CNS function is comparable to other low-sedating antihistamines at the recommended dose of 10 mg/day for adults. It has anti-inflammatory properties that may play a role in asthma management. It does not interact with concomitantly administered medications, it has no cardiac adverse effects, and it does not appear to be associated with teratogenicity. Cetirizine is predominantly eliminated by the kidneys with a mean elimination half-life is 8.3 h. It is rapidly absorbed, and significant clinical inhibition of a wheal and flare response occurs in infants, children and adults within 20 min of a single oral dose and persists for 24 h. No tolerance to the wheal and flare response occurs even after 1 month of daily treatment. The clinical efficacy of cetirizine for allergic respiratory diseases has been established in numerous trials. There is evidence that cetirizine improves symptoms of urticaria. Concomitant use of cetirizine also decreases the duration and amount of topical anti-inflammatory preparations needed for the treatment of atopic dermatitis. Interestingly, several clinical studies suggest that cetirizine may be useful in the treatment and prevention of mild asthma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14680442     DOI: 10.1517/14656566.5.1.125

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  12 in total

1.  An open clinical trial on the efficacy of cetirizine hydrochloride in the management of allergic pruritus in cats.

Authors:  Joya S Griffin; Danny W Scott; William H Miller; Michelle M Tranchina
Journal:  Can Vet J       Date:  2012-01       Impact factor: 1.008

2.  Network-based relating pharmacological and genomic spaces for drug target identification.

Authors:  Shiwen Zhao; Shao Li
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

Review 3.  [New therapeutic strategies for the different subtypes of urticaria].

Authors:  U Raap; T Liekenbröcker; D Wieczorek; A Kapp; B Wedi
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

4.  Cetirizine as a Causative Agent for Drug Induced Methemoglobinemia: A Case Report and Review.

Authors:  Matthew Grillo; Joseph Hong; Sujatha Kosuri; Rita Verma
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Nov-Dec

5.  Cetirizine per os: exposure and antihistamine effect in the dog.

Authors:  Carl Ekstrand; Carina Ingvast-Larsson; Ulf Bondesson; Mikael Hedeland; Lena Olsén
Journal:  Acta Vet Scand       Date:  2018-11-26       Impact factor: 1.695

6.  Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model.

Authors:  Edward J Meier; Gail L Torkildsen; Paul J Gomes; Mark C Jasek
Journal:  Clin Ophthalmol       Date:  2018-12-13

Review 7.  Cetirizine use in childhood: an update of a friendly 30-year drug.

Authors:  Giuseppe Fabio Parisi; Salvatore Leonardi; Giorgio Ciprandi; Angelo Corsico; Amelia Licari; Michele Miraglia Del Giudice; Diego Peroni; Carmelo Salpietro; Gian Luigi Marseglia
Journal:  Clin Mol Allergy       Date:  2020-02-26

8.  An Anti-Cancer Drug Candidate CYC116 Suppresses Type I Hypersensitive Immune Responses through the Inhibition of Fyn Kinase in Mast Cells.

Authors:  Young Hwan Park; Hyun Woo Kim; Hyuk Soon Kim; Seung Taek Nam; Dajeong Lee; Min Bum Lee; Keun Young Min; Jimo Koo; Su Jeong Kim; Young Mi Kim; Hyung Sik Kim; Wahn Soo Choi
Journal:  Biomol Ther (Seoul)       Date:  2019-05-01       Impact factor: 4.634

9.  BSACI guidelines for the management of allergic and non-allergic rhinitis.

Authors:  G K Scadding; S R Durham; R Mirakian; N S Jones; S C Leech; S Farooque; D Ryan; S M Walker; A T Clark; T A Dixon; S R A Jolles; N Siddique; P Cullinan; P H Howarth; S M Nasser
Journal:  Clin Exp Allergy       Date:  2008-01       Impact factor: 5.018

10.  Complementary treatment of allergic rhinoconjunctivitis: the role of the nutraceutical Lertal(R).

Authors:  Gianluigi Marseglia; Amelia Licari; Giorgio Ciprandi
Journal:  Acta Biomed       Date:  2020-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.